Who are Ontak's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ontak, Chrft5, Zenapax, Proleukin, Simulect, Proleukin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/denileukin-diftitox.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ontak — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ontak (DENILEUKIN DIFTITOX) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD25-directed Cytotoxin [EPC]. Area: Oncology.

marketed CD25-directed Cytotoxin [EPC] Interleukin-2 receptor Oncology Recombinant protein Live · refreshed every 30 min

Target snapshot

Ontak (DENILEUKIN DIFTITOX) — Eisai. Ontak works by binding to the interleukin-2 receptor on cancer cells, triggering a toxic response that kills the cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ontak TARGET	DENILEUKIN DIFTITOX	Eisai	marketed	CD25-directed Cytotoxin [EPC]	Interleukin-2 receptor	1999-01-01
Ontak	E7777	Eisai	marketed	CD25-directed Cytotoxin	Interleukin-2 receptor	1999-01-01
Chrft5	BASILIXIMAB	Novartis	marketed	Interleukin-2 Receptor Blocking Antibody [EPC]	Interleukin-2 receptor subunit alpha	1998-01-01
Zenapax	DACLIZUMAB	Hoffman-La Roche	marketed	Interleukin-2 Receptor Blocking Antibody	Interleukin-2 receptor	1997-01-01
Proleukin	ALDESLEUKIN	Chiron	marketed	Lymphocyte Growth Factor [EPC]	Interleukin-2 receptor	1992-01-01
Simulect	Simulect	Astellas Pharma Inc	marketed		Interleukin-2 receptor subunit alpha
Proleukin	Proleukin	University of Minnesota	marketed		Interleukin-2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD25-directed Cytotoxin [EPC] class)

CITIUS PHARMS · 1 drug in this class
Eisai · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ontak — Competitive Intelligence Brief. https://druglandscape.com/ci/denileukin-diftitox. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing